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Abstract The aims of this review are to compare and
contrast the available stereotactic equipment, and to
describe the variety of needle types used and their affect
on pathological results and subsequent patient management.
Initial stereotactic devices were “added-on” to analogue
mammography units and have been replaced by prone or
ducubitus equipment using digital image acquisition.
Biopsies use either 14-G core biopsy (CB) needles or
vacuum-assisted biopsies (VAB). Vacuum-assisted biopsy
systems consistently out-perform 14-G CB with reduced
need for diagnostic or multi-treatment surgery. The false-
negative rate is 8% for 14-G CB compared with 0.7% for
VAB. There is a risk of underestimating the disease present
for lesions of uncertain malignant potential (Cat B3) and
suspicious of malignancy (Cat B4) results with 25% of
patients with a B3 biopsy found to have cancer at
subsequent surgery and 66% of those with a B4 biopsy. A
CB diagnosis of in situ malignancy is upgraded to invasive
disease at surgery in 15-36% of patients undergoing CB
and of the order of 10% with VAB. A high degree of
diagnostic accuracy and hence safe patient care can only be
achieved by meticulous attention to technique and multi-
disciplinary cooperation.
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Introduction
The majority of breast abnormalities are currently biopsied
under ultrasound guidance, however certain mammographic
microcalcifications and small parenchymal deformities are
not demonstrable and thus require stereotactic guidance [1].
Such lesions are almost invariably clinically occult and are
demonstrated on mammography. The widespread introduc-
tion of national mammographic screening programmes,
examining millions of women each year, has led to ever
increasing numbers of stereotactic biopsies [2]. The
diagnosis and management of these lesions, which are
frequently small and of borderline malignant potential,
presents the greatest tests of radiological and pathological
skill [3]. Improvements in guidance techniques and needle
technology have enabled extremely high diagnostic accuracy
to be achieved. The high level of concordance between
pre-operative and surgical diagnoses is essential to
minimize surgical procedures and avoid misdiagnosis
[4]. This said, there is still a need for improvement in
reducing underestimation of disease and refining patient
management of non-malignant high-risk lesions.
In this paper, we aim to compare and contrast the
available stereotactic equipment and describe the variety of
needle types used, as well as their affect on pathological
results and subsequent patient management.
Stereotactic equipment
Stereotaxis uses co-ordinates defined from oblique radio-
graphs to define accurate needle placement. Initial stereo-
tactic devices were “added-on” to standard mammography
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with the patient sitting upright. Acquiring target and needle
position images were slow, patient movement was common
and there was a syncopal rate of approximately 1% [5]. In
the mid 1980s, prone biopsy devices were introduced that
were specifically designed for stereotactic biopsy. Patients
lay prone during procedures, which improved patient
comfort, reduced movement and eradicated syncope. The
additional gravitational effect also facilitated the biopsy of
lesions close to the chest wall.
The advent of digital imaging dramatically reduced
image acquisition time, enabled shorter procedure times
and reduced the likelihood for patient movement. Digital
technology also allowed post-processing (e.g. black-white
image reversal), which may improve calcium visualization
[6]. Although the prone biopsy devices have several clear
advantages over add-on systems, they cannot be utilized
other than for biopsy and are thus expensive and frequently
under-utilized. Also, the calcium retrieval rates using 14-G
core biopsy (CB) and digital stereotactic equipment are
similar at 86% for both prone [7] and upright systems [6].
There is, however, an appreciable syncopal rate associated
with upright biopsy and, although rates as low as 0.3%
have been reported, others have described syncope in up to
35% of patients [8].
During the late 1990s, the add-on equipment was
adapted to enable the procedure to be performed in the
decubitus position [9]. Such systems combined some
advantages of the prone table, such as reduced syncope,
with the ability to perform standard mammography.
Although there is a relative paucity of published data on
the utility of these devices, the advantage of being able to
perform biopsies with the patient lying down and to
undertake standard mammography at other times makes
such devices both cost and space efficient. More recently,
Giotto (manufactured by IMS) have marketed a device
which is capable of performing stereotactic biopsies with
the patient in a prone, upright or lateral decubitus position
as well as undertaking standard digital mammography.
Choice of needle
Initial stereotactic biopsy utilized fine-needle aspiration
cytology (FNAC). Although impressive results could be
obtained, it required a dedicated team of experts, particularly
for cytopathological interpretation [10], and could not be
reproduced when FNAC was introduced on a large scale as
in the UK screening programme [11]. The small size and
frequentpaucicellularityoflesions biopsiedunder stereotaxis,
as well as the lack of reliably identifying calcification in the
biopsy specimen, has meant that FNAC is now discouraged
from use during stereotactic biopsy [12].
Image-guided large-gauge CB was first reported in 1990
[13–16] and was fairly quickly established as the biopsy
technique of choice for the majority of breast lesions. CB
outperforms FNAC on almost all parameters of diagnostic
accuracy [17]. Long-throw 14-G needles produce speci-
mens of approximately 30 mg and outperform smaller
gauges (18 G, 16 G) of CB. When sampling micro-
calcifications, all CB specimens must undergo radiography
to confirm that representative calcification has been
sampled. Bagnall et al. [18] recommended that at least
three flecks of calcification be seen in at least two cores and
preferably five flecks or more should be seen in three cores.
Diagnostic accuracy will depend upon the proportion of a
cluster of microcalcification that is sampled and, as CB
rarely removed an entire cluster, this led to the development
of biopsy devices using vacuum assistance to deliver ever
larger volumes of tissue. The vacuum-assisted biopsy
(VAB) method uses larger gauge probes (11–7 G) than
CB delivering 100–300 mg of tissue per sample. It
incorporates a vacuum chamber to draw tissue into the
cutting needle, where the sample is then taken. This
technique uses just one puncture, with the probe of the
device remaining within the breast, at the site of interest,
throughout the sampling [19].
There are a variety of available VAB devices, each with
different strengths and weaknesses. The first VAB device
marketed was from Mammotome, now a division of
Devicor Medical Products. They currently produce both 8-
G and 11-G needles. The 8-G needle has a blade and is thus
advocated for deployment through dense breast tissue.
Mammotome products also have a variable aperture sleeve
for use in thin breasts and superficial lesions. The
individual specimens need to be removed from the biopsy
chamber by hand and the position of the biopsy chamber is
controlled manually. Suros Surgical Systems, a Hologic
company, produce two levels of product for their second
generation of VAB. ATEC is the standard device that uses
9-G and 12-G needles. It is a closed system that
automatically and continuously irrigates the biopsy cavity.
In addition, the device can be programmed to continuously
acquire specimens every 4.5 s, from pre-programmed
positions in the breast. Eviva is the more advanced system
from Hologic that incorporates a patent-pending Y-valve for
more efficient analgesic application. In addition, there is
better visualization of the specimen cores via an in-built
tocar tip for better tissue penetration. The EnCor Breast
Biopsy System, manufactured by SenoRX, a newly
incorporated division of Bard Biopsy Systems, is a
second-generation VAB. There is a wide variety of needle
sizes available: 7 G, 10 G and 12 G, and there is a half-
sampling option for thin breast or ‘difficult to access’
lesions. The EnCor 360 is an automatic sampling device,
with the probe sampling sweep pre-programmed. The
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Breast Biopsy System is manufactured by Bard Biopsy
Systems. The device supports both 10-G and 14-G needles,
and there are long-probe and larger sampling chamber
options. Although more cost-efficient, the probe needs to be
removed following each specimen core acquisition to
retrieve the core sample. Although the manufacturer has
produced a radiolucent coaxial cannula to aid this, the
multiple entries inevitably result in slower delivery of
specimens.
The larger sample volumes produced by VAB devices
allow more extensive sampling and even complete removal
of some clusters of microcalcifications. Kettritz et al. [20]
in a trial involving 2,874 patients in five centres using 11-G
VAB removed 76% of clusters measuring less than 10 mm
and even removed 30% of clusters measuring 11-20 mm in
diameter. Given this likelihood of complete removal of the
mammographic abnormality, it is now routine practice to
deploy a magnetic resonance imaging (MRI)-compatible
localization clip at the time of biopsy. Greater sampling
yield, however, is accompanied by a 20-fold increase in
price over 14-G CB. Advocates of VAB, however, would
argue that this price increase is offset by a reduced need for
diagnostic surgical excision.
More recently, there has been interest in the utilization of
larger-gauge needles at vacuum biopsy. However, the
evidence to date suggests that there is no significant
difference in pathological upgrade rates using a 9-G over
an 11-G needle [21]. In addition, a separate study
demonstrated that the only significant advantage that an
8-G needle had over an 11-G needle was in the context
of firm breast tissue, where the presence of the bladed tip
aided accurate needle positioning. Importantly, there was
also no statistically significant difference in the compli-
cation rates or their severity when using the larger needle
gauge. However, the larger-gauge needles are generally
more expensive and so their routine use has cost
implications [22].
We will explore the differences in diagnostic accuracy
between VAB and CB by examining the histopathological
results that one might expect with each and discuss their
significance for patient management.
Performance of the stereotactic procedure
Patient amenities should be a priority, as allaying anxiety
prior to the procedure is crucial to patient comfort and
compliance, and eventual successful outcome. Good initial
preparation is paramount and the radiologist should
carefully plan the route of needle placement that optimizes
patient comfort, utilizing theshortest needle track within the
breast without causing damage to the skin. Following
careful patient positioning, meticulous targeting of the
lesion using the scout view and stereotactic paired images
ensures accurate needle placement. Once the local anaes-
thetic is instilled, and the needle has been placed to the
designated position, a further pair of stereo images is
obtained to ensure good needle placement. The tissue
samples are then obtained. After 12-24 cores have been
collected, a specimen radiograph is performed to ensure
that adequate microcalcification has been retrieved. Once
this is confirmed, a localization clip is inserted via the
biopsy needle, and deployed into the biopsy cavity. Post-clip
stereotactic films are then taken to ensure accurate clip
deployment, and the entire biopsy system is removed [23].
Application of pressure locally, following the procedure, aids
to minimize haematoma formation.
Pathology results
European guidelines stipulate that all breast needle biopsies
should be classified to B1–B5 categories according to
histopathological appearances (Table 1)[ 3]. Each biopsy
should be discussed at a multi-disciplinary team meeting,
where both pathological and radiological information can be
used to decide on the best and safest patient management.
Category B1: normal tissue
If no calcium is identified on a specimen radiograph and the
pathologist only identifies normal breast tissue on a biopsy
specimen, then a satisfactory diagnosis has not been
reached. Failure to retrieve calcification occurs in 14% of
CB and 1% of VAB [7]. A false-negative rate of failed
malignancy diagnosis of up to 74% has been reported when
no calcification is evident on the specimen radiograph [18].
Consequently, if no calcium is identified on the radiograph
of specimen cores, then the management of choice is either
a repeat biopsy or diagnostic excision. Early interval
screening should not be considered as a satisfactory
alternative patient management [12].
Category B2: benign lesion
This is the commonest result obtained from a stereotactic
biopsy, whether using CB or VAB, and is obtained between
66 and 75% of biopsies. If a cluster of calcification has
been adequately sampled with extensive amounts of
calcium on the specimen radiograph and the pathologist
finds benign changes associated with visible calcification,
then this is a very safe diagnosis and the patient can be
reliably reassured and discharged without further interven-
tion [3]. When faced with a B1 or B2 biopsy result, the
concern to the breast radiologist is whether malignancy
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negative result varies depending upon the needle type used.
The false-negative rate for 14-G CB is 8% compared with
0.67% for VAB [24]. Assuming the abnormality has been
adequately sampled, there is no current evidence to suggest
that there is a role for specific follow-up in biopsy-proven
benign disease.
Category B3: lesion of uncertain malignant potential,
and Category B4: suspicious of malignancy
These categories mainly consist of lesions which may
provide benign histology on needle biopsy but are known
to either show heterogeneity or have an increased risk of
associated malignancy. The B3 category has a lower rate of
malignancy on further surgical biopsy (25%) when com-
pared with B4 (66%) [3]. The majority of B3 lesions
require surgical excision, but all such patients should be
discussed at a multidisciplinary meeting. A limitation of
non-surgical biopsy that requires consideration is disease
underestimation. It is well documented that there is a risk of
underestimating the disease profile for B3/4 results, i.e.
when a lesion is initially diagnosed as atypical ductal
hyperplasia (ADH) at biopsy and is subsequently upgraded
to ductal cancer in situ (DCIS) following surgery. The rate
of underestimation of ADH to DCIS is between 20 and
56% for CB and 19% for VAB [25–28]. The main
pathological difference between ADH and DCIS is the
amount of involved tissue, and that atypical epithelial
proliferation can be categorized as either B3 or B4,
dependent on severity and extent [29]. It therefore follows
that if sampled tissue volume is maximized using VAB,
then the incidence of disease underestimation will be
minimized. Although there is much debate whether there
is a subset of B3 lesions that might not warrant surgical
excision because their upgrade rate is so low there is, as yet,
no reliable consensus. In addition, all research undertaken
so far has indicated that complete removal of micro-
calcification at VAB should not be considered therapeutic
as residual tumour is often still present at surgery. However,
there is evidence that total removal of the index micro-
calcification does correlate with decreased pathological
upgrade rates at surgery [30]. It is as yet unclear which
histopathological needle biopsy findings, although atypical,
are of sufficiently low risk that surgical excision is not
warranted. This balance between safe clinical practice and
overtreatment is contentious and a unified view has yet to
emerge. As a result, at present, the NHSBSP guidelines
advise surgical diagnostic excision of all B4 lesions and the
management of all B3 lesions should be discsussed at an
multi-disciplinary team meeting [29]. There is no current
evidence to suggest further imaging is of benefit when a
representative tissue sample has been obtained.
Category B5: malignant
These can be subdivided into malignant in situ (Cat: B5a)
or malignant invasive (B5b) [29]. When sampling micro-
calcification, DCIS is the commonest malignancy diag-
nosed and constitutes 20% of screen detected cancer [2, 4].
As with B3/B4 lesions, underestimation of disease is
possible where a B5a (in situ malignancy) is upgraded to
invasive malignancy following surgery. The underestima-
tion rate is again dependent upon the needle type used. A
CB diagnosis of DCIS is up-graded to invasive disease at
surgery in 15-36% of patients, whereas of the order of 10%
Table 1 Categories of pathological interpretation of large-gauge core or vacuum-assisted breast biopsy as specified in the European guidelines for
quality assurance in breast cancer screening and diagnosis [3]
Category Description Examples
B1 Normal Normal tissue or uninterpretable
B2 Benign lesion Fibrocystic change,
fibroadenoma,
sclerosing adenosis,
duct ectasia,
fat necrosis
B3 Lesion of uncertain potential Papillary lesion,
radial scar/complex sclerosing lesion,
lobular intraepithelial neoplasia,
atypical ductal hyperplasia,
phyllodes tumour,
mucocele-like lesions.
B4 Suspicious of malignancy Atypical ductal hyperplasia
B5 Malignant May be subdivided into malignant-in-situ or malignant invasive
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likelihood of upgrade to invasive disease are the number of
flecks of microcalcification, the size of the cluster and the
grade of the DCIS. Clusters that contain more than 40
pieces of calcification have a 48% chance of invasion at
final histology compared with 15% for clusters with less
than 40 pieces of calcification. Clusters that are less than
11 mm in diameter have an 18% chance of invasion at final
histology compared with 35% for clusters 60 mm or more
in diameter [32]. Thirteen percent of patients initially
diagnosed with low grade DCIS will be upgraded to
invasive disease, compared with 36% of those with high-
grade DCIS [33]. This has important consequences for
patient management. As the majority of patients with
invasive disease will require surgical axillary staging,
surgeons not infrequently perform axillary surgery in
patients with biopsy-proven DCIS if upgrade to invasion
is thought likely at surgery. As a consequence, data from
the UK show that 31% of patients with a final diagnosis of
DCIS only will also have had their nodal status ascertained
at the time of breast surgery [4]. The vast majority of these
patients will have undergone mastectomy, however 10% of
patients undergoing conservation therapy for DCIS had also
undergone axillary staging. Although this will almost
invariably be in the form of sentinel lymph node biopsy,
of proven low morbidity, it nonetheless constitutes an
unnecessary surgical procedure.
The importance of accurate non-operative diagnosis
cannot be underestimated. It enables the safe discharge of
those patients with benign disease and the planning of
correct surgery for those with malignancy [34].
Complications
The complication rates of stereotactically guided needle
biopsy are surprisingly low, and any adverse events are
usually minor. Reported complications include bruising,
discomfort, haematoma and abscess formation. The rate of
requirement for surgical drainage of an abscess or haematoma
is in the region of 0.1% [19]. Seeding of tumour cells has
been reported but does not appear to be of clinical
significance [35].
Conclusions
The sensitivityandspecificityofstereotacticallyguidedlarge-
core-needle breast biopsy is high, even for small mammo-
graphic distortions and microcalcifications. Vacuum-assisted
biopsysystemsconsistentlyout-perform14-GCB,withlower
disease underestimation and false-negative rates, and the
reduced need for diagnostic or multi-treatment surgery offsets
the considerable added procedural expense. Although a high
degree of diagnostic accuracy is achievable, even on a
national scale (84% of the 3,491 patients with screen-
detected DCIS were diagnosed pre-operatively in the
UK screening programme in 2008-2009) greater efforts
are required to minimize the false-negative rate and the
underestimation of DCIS and invasive malignancy [4]. It is
only by meticulous attention to technique and a high degree
of multi-disciplinary cooperation that diagnostic accuracy
will increase with consequent improvement in patient care.
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